Skip to main content

Advertisement

Table 2 Mean MARINA study vision levels (years 1–2), HORIZON extension trial (years 3–4), then last observation carried forward to year 12 in the 0.5 mg treatment cohort, with a meta-analysis control cohort from years 3–12

From: The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited

Time Control cohort 0.5 mg treatment cohort
Baseline 20/80 − 1 20/80 − 1
6 months 20/100 − 2 20/63
12 months 20/126 20/63 + 1
18 months 20/160 + 2 20/63 + 1
24 months 20/160 − 1.5 20/63 + 1
3 years 20/250 20/63 + 1
4 years 20/320 20/80 + 2
5 years 20/400 20/80 + 1
6 years 20/500 + 2 20/80 + 1
7 years 20/500 20/80 + 1
8 years 20/640 + 2 20/80 + 1
9–12 years 20/640 20/80 + 1